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Abstract
Background: Limited treatment options are available for patients infected with multidrug (MDR)- or pan-drug (PDR)-
resistant bacterial pathogens, resulting in infections that can persist for weeks or months. In order to better understand
transmission and evolutionary dynamics of MDR Acinetobacter baumannii (Ab) during long-term infection, we analyzed
genomes from a series of isolates from individual patients at isolate-specific, patient-specific, and population levels.
Methods: Whole genome analysis of longitudinal isolates (range 2-10 isolates per patient spanning 0-829 days) from
40 patients included detection of single-nucleotide variants (SNVs), insertion sequence (IS) mapping, and gene content
changes.
Results: Phylogenetic analysis revealed that a significant fraction of apparently persistent infections are in fact due to
re-infection with new strains. SNVs primarily resulted in protein coding changes, and IS events primarily interrupted
genes or were in an orientation such that the adjacent gene would be over-expressed. Mutations acquired during
infection were over-represented in transcriptional regulators, notably pmrAB and adeRS, which can mediate resistance
to the last line therapies colistin and tigecycline, respectively, as well as transporters, surface structures, and iron
acquisition genes.
Conclusions: Most SNVs and IS events were isolate-specific indicating these mutations did not become fixed on the
time scale investigated, yet over-representation of independent mutations in some genes or functional categories
suggests that they are under selective pressure. Genome analysis at the population-level suggests that gene transfer
including recombination also contributes to Ab evolutionary dynamics. These findings provide important insight into
the transmission dynamics of Ab and the identification of patients with repeat infections has implications for infection
control programs targeted to this pathogen.
Background
Bacterial pathogens resistant to multiple classes of antibi-
otics are increasingly detected in clinical settings, and pa-
tients with multidrug-resistant (MDR) infections have
limited treatment options. This occurrence can translate
into prolonged infections with increased morbidity and
mortality [1, 2]. Analysis of MDR strains isolated over time
from individual patients during infection and treatment
can reveal important adaptations to the host environment
[3–5]. The most extensive work to date has characterized
longitudinal genome changes in cystic fibrosis patients
infected with Pseudomonas aeruginosa and Burkholderia
species, where these studies found that mutations were
enriched in genes related to host adaptation and antibiotic
resistance, and observed the co-existence of multiple line-
ages in the same host [6–10]. Patients with cystic fibrosis
experience long-term infections, often spanning many
years. Fewer studies have examined genomic changes in
the context of acute infections that persevere during
hospitalization, nor have longitudinal genomic changes
within the context of a broader population structure been
assessed.
In the last decade, Acinetobacter baumannii (Ab), one of
the ESKAPE pathogens, emerged to become a predomin-
ant cause of nosocomial infections [11–14]. This is in part
due to a remarkable rise in the frequency of MDR (resist-
ant to at least three classes of antibiotic) and extreme drug
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resistant (XDR; resistant to all antibiotics except tige-
cycline or colistin) infections [12–14]. Notably, infec-
tions with carbapenem-resistant MDR and XDR strains
are associated with longer hospitalization, greater economic
costs, and higher mortality vs. carbapenem-susceptible
strains [15–23].
Increased antibiotic resistance in Ab has been primarily
driven by acquisition of resistance determinants encoded
on mobile genetic elements and activation of intrinsic
resistance mechanisms such as the chromosomal β-
lactamases, blaOXA-51-like and blaADC, and increased activ-
ity of efflux pumps such as adeABC [24, 25]. A large
‘resistance island’ encoding more than a dozen antibiotic
resistance genes was found in one of the first MDR Ab
strains to be sequenced [26], and sequencing of hundreds
of additional strains has shown that resistance genes are
often associated with plasmids [27, 28]. The ISAba1 elem-
ent and other insertion sequences have also contributed to
antibiotic resistance by activating expression of intrinsic
resistance genes adjacent to their insertion sites [29].
ISAba1 elements are abundant in some Ab strains, and
the location of ISAba1 insertions can add resolution to
population dynamics and genomic epidemiology [30], but
the role of these elements in adaptation to selective
pressures during infections has not been addressed.
Clinicians have observed that in treating Ab infec-
tions, some patients remain chronically infected for pro-
longed periods of time. Whether long-term infected
patients are the result of the persistence of one strain
due to treatment failure, or new infection by a different
strain, remains a pressing question. Genome sequencing
provides an opportunity to address this question. We
previously characterized the genetic profiles of Ab
strains isolated from a large hospital system in the Mid-
western USA and found considerable diversity including
evidence for multiple closely related lineages and exten-
sive variability of mobile elements [30]. In this follow-
up study, we sought to understand what genome
changes occur during the course of infection and anti-
biotic treatment. We therefore decided to sequence all
available strains from patients that had multiple positive
Ab cultures to characterize the nature of genetic change
during infections. Longitudinal analysis of isolates col-
lected during the course of infection and treatment can
provide insight into infection history, and how Ab re-
sponds to host and antibiotic selective pressures.
Methods
Strains
A. baumannii strains identified in the University Hospitals
Health System (UHHS) Clinical Microbiology Laboratory
were stored in an archive since 2007. We identified all pa-
tients for which there were more than two isolates available
in the archive as of 1 December 2013, and those isolates
were selected for whole genome sequencing. A total of 136
new strains were sequenced and these genomes were
combined for analysis with previously described sequences
from UHHS [30] for a high resolution population-level ana-
lysis. Repeat cultures were ordered when patients presented
with continued signs of infections. Clinical data, including
treatment history and outcome, were collected from patient
charts. The research study was reviewed and approved by
the Institutional Review Board of the University Hospitals
Case Medical Center, and conformed to the Helsinki
Declaration.
Sequencing
Overnight cultures were grown in LB broth and DNA
was isolated using an UltraClean® Microbial DNA Isola-
tion Kit (MoBio, Inc.) using a protocol implemented on
an Eppendorf EpMotion automated pipetting device.
Libraries were prepared for sequencing using Illumina
NexteraXT kits and sequenced on an Illumina HiSeq
2000 with paired 100-base sequence reads. In general,
more than 100-fold coverage was obtained for each
genome. Each read set was assembled individually
using velvet [31] and annotated using NCBI’s PGAAP
pipeline (http://www.ncbi.nlm.nih.gov/genome/annota-
tion_prok/). All genomes are available at NCBI under
BioProject PRJNA262565.
Phylogenetic analysis
A core phylogeny based on single nucleotide variants
(SNVs) was inferred using SNVs identified by kSNP [32]
and constructed using RAxML [33] with previously
sequenced UHHS and other publicly available genomes
included for phylogenetic context [30]. Genome positions
with allele calls in at least 80 % of strains were included in
the analysis. Regions of the genome subject to recombin-
ation were excluded from consideration in construction of
the core phylogeny as in Wright et al. [30].
Variant detection analysis
A more stringent approach was used to identify patient-
restricted and isolate-specific SNVs from all patients with
monophyletic isolates. Primary Illumina sequence reads
were aligned to patient-specific reference genome assem-
blies, typically the earliest isolate from each patient, using
bwa. To avoid the impact of low-quality sequences at
contig edges, SNVs within 200 bases of contig edges were
excluded. Variant-calling was performed using freebayes
(arXiv:1207.3907 [q-bio.GN]) with a requirement for ≥20-
fold coverage of the alternative allele with no reads
supporting the reference allele, and a minimum SNV qual-
ity of 500. SNVs identified when reads from the reference
genome were aligned to the reference contigs were
excluded as likely indicating errors in the reference assem-
bly. Patient-specific SNVs were identified as those SNVs
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uniquely shared within a patient based on the kSNP out-
put for the full set of SNVs annotated to the reference Ab
ACICU genome. ACICU was the first sequenced MLST
ST2 (Global Clone 2) isolate, obtained from Italy in 2005
[34], and was selected as a reference because the majority
of isolates in this study are GC2. Synonymous/non-syn-
onymous status was inferred based on alignment of flank-
ing sequences to the ACICU annotation.
Genome variation analysis
To identify gene gain and loss events during infection,
pan-genome analysis was performed using PanOCT [35].
The locations of IS elements in the draft genome assem-
blies was performed using ISSeeker, a custom perl script
(https://github.com/JCVI-VIRIFX/ISseeker). IS locations
in each genome were mapped to the common reference
genome ACICU. The two most abundant IS elements in
this population, ISAba1 and IS26 were examined and
isolate-specific and patient-specific insertion sites were de-
termined and mapped to the ACICU annotation.
Functional enrichment analysis
Functional roles and pathways were assigned using KEGG
designations [36] and TIGRfams [37] for each non-
synonymous SNV and non-neutral IS event, and the num-
ber of genes within each category was determined for
ACICU. To identify statistically significant enrichment in
functional classes of genes, hypergeometric probability
tests were conducted. In the calculation, the population
size was the number of all genes in the PanOCT shared
clusters for the 136 genomes (553,343 genes); the popula-
tion successes value was calculated as the number of genes
in each functional role or pathway category based on its
abundance in ACICU multiplied by each genes’ occur-
rence in the PanOCT shared clusters; sample size was the
number of SNV or IS events for isolate-specific (IS),
patient-restricted (PR), or patient-specific (PS) categories,
respectively; and the number of sample successes was the
number of hit genes in each category.
Results
Isolate characteristics
Genome sequences were obtained for 136 Ab isolates
from 40 patients (Additional file 1: Table S1 and
Additional file 2: Table S2). The number of isolates per
patient was in the range of 2-10, over 0-829 days between
first and last isolation (Additional file 1: Table S1). The pat-
tern of antimicrobial susceptibility indicated that 125/136
isolates were resistant to ≥3 classes of antibiotics and are
thus considered MDR. Isolates were collected from an
integrated healthcare system: a central referral hospital
(92/136), outlying community hospitals that were part of
the healthcare system (23/136), long-term care facilities
(16/136), and outpatient clinics (5/136). The isolates were
collected from patients evaluated in an ICU, general med-
ical wards, and from the emergency department. The 136
genomes were placed in the context of other UHHS
genomes detailed in Wright et al. [30], and 22 publicly
available reference genomes using a phylogeny constructed
from 50,466 core SNVs located in non-recombinant
regions of the genome (Fig. 1).
A patient was considered to have an infection stem-
ming from one colonization event when all of the iso-
lates from that patient were located on a monophyletic,
well-supported terminal node of the core phylogeny.
Twenty-five patients had such monophyletic infections
(Fig. 2, Additional file 1: Table S1). Fifteen patients had
polyphyletic infections with isolates located at clearly dis-
tinct branches of the phylogenetic tree, indicative of at
least two independent colonization events. Two of these
patients have co-occurring polyphyletic infections in which
phylogenetically distinct strains were isolated in overlap-
ping time intervals, while the other 13 polyphyletic patients
were likely re-infected with new strain types. In some
cases, multiple related (monophyletic) strains were isolated
from patients that were also infected with genetically
distinct strains (polyphyletic). There was no relationship
between the number of days separating culture-positive
isolations and the likelihood of whether a new isolate was
closely related (monophyletic) or represented a reinfection
(polyphyletic) (Additional file 1: Table S1). The site of
infection also did not predict whether subsequent isolates
would be related: there are examples of both monophyletic
(for example, Patient 236) and polyphyletic infections (for
example, Patient 348) occurring at different body sites in
the same patient.
Monophyletic isolates
SNVs in monophyletic groups from individual patients
were of particular interest and were examined in more
detail. Three classes of SNVs were defined: isolate-specific
(IS) SNVs were found only in a single isolate; patient-
restricted (PR) SNVs were found in multiple isolates (but
not all) from a single patient; and patient-specific (PS)
SNVs were shared by all isolates from a patient. For all
three classes, the SNVs were not observed in any other
UHHS or public reference strain. The complete list of
these SNVs with gene annotations is presented in
Additional file 3: Table S3. Most of the SNVs that oc-
curred during infection were unique to each isolate: of the
220 detected SNVs, 189 (86 %) were isolate-specific. IS
SNVs arising during infection were detected in 31 strains
(mean 4.8 SNVs, range 0-29 SNVs/patient). PR SNVs were
identified in nine patients (range: 0-8 SNVs/patient).
There was no relationship between the number of
SNVs per isolate and the number of days between
isolations (Fig. 3). For example, the three isolates
from Patient 236 collected on the same day had eight
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SNVs among them, while three isolates from Patient
195 over 48 days had 0 detected SNVs among them.
Isolates from distinct body sites did have more isolate-
specific SNVs. For example, the two Clade B isolates from
Patient 184 had 14 (percutaneous endoscopic gastrostomy
site) and 15 (urinary tract infection) IS SNVs. SNVs that
were restricted to a patient had a higher proportion of
non-synonymous (NS) amino acid substitutions com-
pared to synonymous (S) substitutions (NS/(NS + S):
0.97) than the isolate-specific (0.77) and patient-specific
SNVs (0.74) (Table 1) yet all categories of isolate- and
patient-restricted SNVs were strongly skewed towards
non-synonymous mutations relative to the population-
level NS/(NS + S) ratio of 0.18.
Fig. 1 Core SNV phylogeny of A. baumannii strains. A core phylogeny was constructed using 50,472 SNVs that were present in at least 80 % of all
strains. SNVs were identified using kSNP and the tree was built using RAxML. Clade A-E designation reflect primary clade structure previously designated
[30, 44] where strains in Clade A-D through the ACICU branch are all Global Clone II, or multi-locus sequence type (MLST) ST2, strains [60]. Internal nodes
with bootstrap support of at least 50 % are indicated. Black circles near terminal nodes indicate highly-supported monophyletic groups of strains from
individual patients. Strain names are color-coded based on the hospital from which the isolate was obtained and the first the numbers after ABUH refer
to patient and strain identifiers in Additional file 1: Table S2. Colored dots represent the presence of specific genes or genomic regions of interest as listed
in the key
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ISAba1 is abundant and dynamic in the UHHS popula-
tion, and mapping of the insertion sites for ISAba1 revealed
additional genomic modifications during infection. Similar
to SNV patterns, most new ISAba1 insertions were isolate-
specific and these tended to be in coding regions or in an
orientation that would result in overexpression of an adja-
cent gene (Table 1, Additional file 4: Table S4). Only three
patient-restricted IS events were detected, two of which are
predicted to result in the overexpression of downstream
genes. Independent ISAba1 insertions upstream of the
fimA gene in two different patients were predicted to lead
to overexpression of the type-1 fimbrial protein. A smaller
fraction of patient-specific IS events (uniquely shared
among all isolates from a patient) were in coding sequences
or an overexpression orientation, while across all UHHS
isolates, ISAba1 was less likely to be found in an overex-
pression orientation.
The 10 strains isolated from Patient 243 provide par-
ticularly illustrative examples of SNV and ISAba1 patterns
associated with temporal and spatial heterogeneity. Six
isolates encompassing respiratory, urine, and abdominal
sites of infection had no detectible SNVs among them,
including three isolates cultured 8 days after the initial
sample. The other four isolates had between two and six
SNVs relative to Day 0 isolates. All but one these SNVs
were isolate-specific, where the mutation in the RNA
polymerase gene rpoB was present in two Day 8 abdom-
inal fluid isolates. No ISAba1 insertions that arose during
infection were shared among Patient 243 isolates. SNV
patterns from Patient 236, on the other hand, reveal
that spatial isolation can lead to strain differentiation.









































































Fig. 3 Relationship between SNV frequency and time between strain
isolations The number of within-patient SNVs is shown as a function of
time for isolate-specific and patient-restricted SNVs for each patient
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branch with distinct SNVs and gene content from other
UHHS strains. The blood and abdominal fluid isolates
(ABUH23684 and ABUH23685) have three shared SNVs
and one ISAba1 insertion not present in ABUH23687
(a scrotal isolate) which has two unique SNVs.
Gene content changes in monophyletic isolates were
primarily gene loss events centered around IS26-medi-
ated deletions in the astA and ACICU_02399 Tn1548
resistance island regions described in [30]. IS26 has been
shown to cause deletions of adjacent sequence [38, 39].
We observed a partial deletion of Tn1548 at the catB
gene in ABUH315100 which resulted in the loss of the
amikacin resistance gene, armA, and independent losses
of the adjacent csuE region in multiple isolates as best
depicted by the variable presence of csuE in isolates
from clades B and D (Fig. 1). Variation in phage content
was observed in Patient 410 in a region previously de-
scribed as dynamic [30]. The first Patient 410 isolate had
one 48 kbp region of phage sequence, the second had an
additional 36 kbp of sequence, and the last two isolates had
an additional 13 kbp of sequence in this region, resulting in
a variable phage region in the range of 48-97 kbp in size.
Polyphyletic isolates
Two patients had co-occurring polyphyletic infections in
the same infection site: bronchial specimens from Patient
367 and Patient 455 produced isolates from different clades.
There was no evidence for genetic exchange between the
Clade A strains in Patient 367 and the more divergent
ABUH367558, which was isolated at an intermediate time
point between the two clade A strains. The two clade A
strains are isogenic, as they share a terminal branch on the
tree, with only three SNVs that distinguish them and a
uniquely shared ISAba1 insertion in a gene encoding the
histidine kinase protein of an uncharacterized two compo-
nent regulatory system (TCRS) (ACICU_03157). This strain
persisted largely unchanged during the 77 days between
isolations. Genetic exchange did occur between the two dif-
ferent strain types in Patient 455: pABUH1 was transferred
from the clade A strain to the clade B strain (ABUH45561
to ABUH45538/ABUH45562) as previously described [30].
Thirteen patients had polyphyletic infections where re-
infection or replacement with a new strain type was likely.
Clade A strains carry the most resistance determinants
and were not replaced with a different strain type in this
population.
Enrichment and convergence
Analysis of the functional categories of genes with SNVs
and IS insertions demonstrated that genes associated with
antibiotic resistance and host interaction are over-
represented (Table 2). The most commonly mutated genes
were pmrAB that encode the two component regulatory
system (TCRS) involved in mediating colistin resistance
through modification of surface polysaccharides and
membrane charge [40–43]. Twelve patients had at least
one isolate with a mutation in pmrA or pmrB and four of
those patients had multiple strains with independent mu-
tations (Fig. 4a). The adeRS genes, which encode a TCRS
that regulates expression of the efflux pump operon
adeABC, were the second most commonly mutated loci,
found in isolates from 12 patients (Fig. 4b). Seven patients
had mutations in both the pmrAB and adeRS TCRS genes.
Another uncharacterized histidine kinase component of a
TCRS, ACICU_03157, had both ISAba1 and point muta-
tions in three patients. Transporters were also significantly
enriched, accounting for 30 out of 123 non-synonymous
SNVs in the isolate-specific SNV set. This included
multiple cation (copA, znuB (two independent mutations)
and arsB) and iron-related transporters (fhuE (two inde-
pendent mutations), feoB, and siderophore transporters),
as wells as antibiotic transporters including the porin
carO, adeB, and adeJ efflux pumps, and those associated
with lipopolysaccharide export, msbA and lptF. The iron
Table 1 SNV and IS event summary
SNV Intergenica Synonymous Non-synonymous NS/(N + S)
Isolate-specific 30 (16) 36 123 0.77
Patient-restricted 2 (7) 1 28 0.97
Patient-specific 58 (15) 83 237 0.74
Population-levelb 10,709 (9) 85,865 19,190 0.18
ISAba1c Overexpressed Loss of function Neutral Total
Isolate-specific 8 (33) 13 (54) 3 (13) 24
Patient-restricted 2 (67) 0 1 (33) 3
Patient specific 8 (32) 10 (40) 7 (28) 25
Population-level 13 (15) 50 (60) 21 (25) 84
aValues in parentheses are the percentage of SNVs that are intergenic
bSummary from kSNP output analyzing the 136 longitudinal isolates, and UHHS and public genomes
cValues in parentheses are the percentage of IS events in each category
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acquisition gene, iucD, had both NS SNV and IS mutations
in strains from four patients (Fig. 3c). Motility and adhesion
related genes were also significantly enriched (for example,
csuE, pilG, and fimA). Mutations in the tyrosine kinase wcz
gene involved in capsular polysaccharide assembly were de-
tected in three patients, while UDP-N-acetylmuramate-ala-
nine ligase murD mutations were observed twice. The
RNA polymerase III gene, rpoB, had three NS mutations in
two patients; all of the SNVs were located in the rifampin
resistance-determining region (RRDR).
ISAba1 insertion sites also tended to be in genes with
functions in antibiotic resistance and host adaptation.
Genes encoding transporters (including AdeABC efflux
pump), transcriptional regulators, surface-associated genes,
and secreted and adhesion genes like papD and fimA, were
all modified by ISAba1 (Additional file 4: Table S4).
New insights into the population structure of
A. baumannii population at UH
The primary clade structure described previously is un-
changed with the addition of the strains analyzed here [30,
44]. Clade A is most abundant, with 58 isolates. The ana-
lysis of the expanded set of UHHS strains revealed that
there are two clade A subgroups that differ in the presence
of a region that encodes a heme oxygenase, hemO, (Fig. 1)
that was previously described as a recombination hotspot
[30, 45, 46]. There is evidence for more divergent strains
among the most recent isolates that carry new genetic ma-
terial, including the blaOXA-72 variant of the blaOXA24/40-type
carbapenemase gene in ABUH588656 and ABUH588663.
There is now evidence for recombination at the blaOXA-51
locus in clade C, with a different allele now present.
Epidemiological and genomic data highlight multiple
cases of likely patient-to-patient transmission. For ex-
ample, the clade A cluster of isolates from Patients 243,
315, and 487 all occurred in the ICU within the span of a
few days in 2007. These three patients share four unique
SNVs, while Patients 243 and 487 share an ISAba1 event.
Similarly, Patient 66 and Patient 514 overlapped in the
ICU in 2008 and had nearly identical clade B isolates with
one shared SNV (1 bp upstream from start of ACICU_
01396, a predicted MFS transporter).
Patients with persistent infections move among hos-
pital locations during the course of treatment. Eleven
patients contributed isolates obtained in more than one
hospital, with transfer between a long-term care facility
(LTCF) and the tertiary care hospital being the most
common transfer route (four patients moved to LTCF,
four patients were transferred from a LTCF to the main
or regional hospitals). Patient 392 was infected with
three different strains over the course of >800 days, each
isolated during a stay at a different community hospital.
Patient 225 was infected with a monophyletic set of
strains from clade A over 170 days, with strains isolated
during the patient’s stay at a LTCF, the main ICU ward,
a community hospital, and again at the main ICU ward.
Discussion
Two lines of evidence suggest that natural selection is con-
tributing to the range of SNVs and IS insertions observed in
the series of longitudinal isolates from each patient. First,
genes involved in antibiotic resistance and host interaction
were significantly enriched for novel genetic variants. MDR
strains have limited treatment options, resulting in an in-
creased reliance on last-line therapies like colistin and tige-
cylcine. The pmrAB genes were the most frequently
mutated, with 18 independent mutations and IS events ob-
served. These mutations tended to occur in patients that
had been treated with colistin: 12 patients had isolates with
mutations in these loci, and at least nine of them received
colistin therapy. Colistin treatment status was unknown for
the other three patients due to incomplete patient histories.
Mutations in pmrAB that arise during treatment have been
described previously [47]. Ample evidence supports a role
Table 2 Enrichment analysis of genes with SNV and IS events. Significant enrichment in classes and pathways assessed using
hypergeometric distribution test based on abundance of genes in each category in ACICU, integrated with PanOCT shared clusters
















Transporters 282 30*** 4 23* 3 0 2
Transcription factors 207 5 2 20** 2 0 4*
Two component regulatory system 26 19*** 5*** 11*** 2 0 4
Lipid A and capsular polysaccharide synthesis 54 7** 2* 5 1 0 0
Iron transport 64 8** 1 4 0 0 1
Motility 31 4* 1 3 1 1 1
Total non-synonymous and non-neutral events
used in hypergeometric test calculations
123 28 215 21 2 18
* <0.05, ** <0.005, *** <0.0005
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for the TCRS system PmrAB in regulation of colistin resist-
ance in Ab through upregulation of pmrC, a lipid A phos-
phoethanolamine transferase [41, 42]. Some relationships
between pmrAB mutation and colistin minimum inhibitory
concentration (MIC) were observed. For example, the MIC
for isolate ABUH41489 with an ISAba125 interruption
of pmrB was >128 ug/mL, while isolate ABUH41488
from the same patient, which had a pmrA mutation
(I173F) had a MIC measured at 2 ug/mL. However, the
majority of strains with pmr mutations had MIC values
Fig. 4 Selected loci with multiple independent mutations. Genes and gene regions that exhibited a significantly over-representation of mutation
frequency are shown. a The pmrCAB genes encode the PmrAB TCRS that is associated with resistance to colistin and one of the target genes (pmrC),
that encodes a lipid A phosphoethanolamine transferase. b The adeABC genes encode an RND family efflux pump that is involved in resistance to
several classes of antibiotics. The adeRS genes encode a TCRS that regulates adeABC. c A region encoding several genes involved in siderophore
biosynthesis. Iron acquisition mediated by siderophores is an important adaptive mechanism in the host environment that is characterized by limited
free iron concentrations
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<2 μg/mL, which is considered phenotypically susceptible
in standard clinical assays (Additional file 2: Table S2). A
recent study of the development of resistance in the con-
text of colistin therapy in A. baumannii showed that clin-
ical colistin resistance can go undetected by standard
clinical methodologies [48]. Though phenotypically suscep-
tible, pmrC expression values were significantly increased
from 5-30-fold in three strains tested relative to their iso-
genic parental strains from the same patient (RNASeq data
not shown). Thus the elevated pmrC expression suggests
that pmrAB mutations in these strains may result in lipid A
modifications that confer some level of protection from co-
listin. Mutations in lpxACD, encoding for lipid A biosyn-
thesis pathway, have also been implicated in conferring
colistin resistance [49]. We did not observe any mutations
in the lpx genes, supporting the prediction that pmrAB
mutations are likely to be the most commonly encountered
colistin resistance mechanism in Ab in clinical settings due
to a higher fitness cost of lpxACDmutations [50].
Another TCRS, adeRS, and its associated efflux sys-
tem, adeABC, also had multiple independent mutations
in this population, with 16 independent mutations and
IS events in 12 patients. AdeRS regulates the expression
of the adeABC efflux pump genes which are associated
with resistance to several antibiotics including to tige-
cycline [51, 52]. Sequence variation is high in these
genes as observed previously and related to tigecyline re-
sistance [53]. Interestingly, only three patients with adeRS
or adeABC mutations in this study were confirmed to
have received tigecycline during treatment, while four did
not, and five patients had inconclusive patient records. All
adeRS and adeABC mutant isolates had tigecycline MIC
values >2 μg/mL (Additional file 2: Table S2), indicative of
a resistant phenotype. Eight of the 14 mutations were
patient-specific, meaning that even the initial isolate had
the mutation. This observation is consistent with the hy-
pothesis that the regulation of adeABC is under selection
for more than just tigecycline efflux [51]. Mutations in the
rpoB gene encoding RNA polymerase III can confer resist-
ance to rifampin. Three isolates from two patients had
rpoB mutations in the rifampin resistance determining re-
gion (RRDR) [54] and both patients received rifampin
therapy in combination with colistin. This suggests that
mutations in other multiply-mutated genes may also have
adaptive value in the context of infection.
MDR infections still have to persist in the context of the
host immune system, and functional categories related to
regulation of transcription, membrane transport, surface
polysaccharide synthesis and organization, iron acquisition,
and motility were enriched in mutations. Mutations were
observed in the tyrosine kinase wzc gene involved in
mediating capsular polysaccharide organization [55–57].
Notably, several mutations occurred in genes encoding iron
acquisition and siderophores with potential implications for
iron acquisition during host infection. The enrichment in
transcription factors in SNV and IS events raises the ques-
tion of how the transcriptional landscape changes during
infection. For example, the histidine kinase component of
an uncharacterized TCRS, ACICU_03157, had both SNVs
and IS mediated changes in this population.
The second line of evidence of a role for natural
selection in the set of observed SNVs is the elevated
ratio of non-synonymous variants compared to the
population-wide average (Table 2). Isolate-and patient-
specific SNVs were much more likely to be non-
synonymous than SNVs observed in isolates from multiple
patients. SNVs in multiply-hit genes also have higher non-
synonymous ratios at the population level compared to the
population mean ((NS)/(NS + S) = 0.18) (Additional file
5: Table S5), suggesting that these genes may be sub-
ject to diversifying selection, in contrast to those
genes below the population-wide value. For example
the iron-related genes, ACICU_01673, ACICU_01696,
ACICU_02572, and ACICU_02581, all have population-
wide ((NS)/(NS + S) >0.35. Furthermore, siderophore syn-
thesis genes, transporters, and TCRS, were also observed
in strain-specific SNVs in an Ab outbreak [58]. Functional
gene enrichment findings are also in agreement with other
longitudinal studies including persistent and asymptom-
atic Burkholderia pseudomallei infection which had key
changes in lipopolysaccharide biosynthesis and modifica-
tion [10], and those observed during 12 weeks of
Staphylococcus aureus blood stream infection that
included transporters and antibiotic resistance genes [4].
Lieberman et al. (2014) found extensive diversity of
Burkholderia dolosa in individual CF patients, with mul-
tiple adaptive mutations appearing, but few becoming
fixed in the population over time [6]. In a longitudinal
study of over 400 Pseudomonas aeruginosa strains isolated
from 34 CF patients, convergent evolution was identified
in several genes involved in host adaptation based on
remodeling of regulatory networks [59]. An alternative
explanation, however, for the elevated rate of non-
synonymous mutations is that there has not been ad-
equate time for deleterious mutations to be removed from
the population. This alternative hypothesis predicts that
over time the fraction of non-synonymous mutations
would decline. More extensive sampling of infected
patients will be required to better understand the
spectrum of mutations that arise during infection and
make inferences about their functional effect.
Hospital-acquired infections are generally considered acute
and treatable. Increasing rates of antibiotic resistance are
changing that perception. Strains resistant to all FDA-
approved drugs now represent a significant fraction of Ab in-
fections in many hospitals and have led to long-term
infections that are difficult to treat. Relatively few studies
have examined the evolution of bacterial pathogens during
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long-term infections. We found that patients persistently in-
fected with MDR Ab are due to both treatment failure and
re-infection with new strains. Multiple examples were found
of patients infected with the same strain for >150 days. Pa-
tient movement data highlight the need to monitor patients
with a history of MDR Ab as they are admitted to a new
hospital unit.
A limitation of this study is that serial sampling of
infected patients was not performed in a systematic or
prospective manner, but relied on a convenience sample
that may introduce biases. Another limitation is that a
single isolate was sequenced from each culture date and
so we were not able to evaluate the population of variants
that were present in a patient at any given time. In some
cases the retrospective sampling design does not distin-
guish between co-occurring, replacement, or re-infection
scenarios. To more rigorously distinguish between these
classifications, multiple isolates from multiple time points
need to be analyzed. Nonetheless, we were able to show
that both long-term infections and super-infections with
genetically distinct strains are common.
Conclusions
Genomic analysis of A. baumannii isolates collected
from the same patient over time revealed enrichment in
mutations associated with antibiotic and host responses,
including those encoding for transcriptional regulators,
cell surface structures, and iron utilization. Most muta-
tions were isolate-specific, yet enrichment analysis
suggests that the much of the genetic variation detected
is under selection.
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